DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications
β Scribed by Nicola Tinari; Clara Natoli; Domenico Angelucci; Raffaele Tenaglia; Bruno Fiorentino; Pia Di Stefano; Cristina Amatetti; Andrea Zezza; Michele Nicolai; Stefano Iacobelli
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 638 KB
- Volume
- 71
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Clinical use of flow cytometric (FCM) DNA analysis requires effective quality controls. Thirty-two laboratories with various degrees of FCM experience participated in the first phase of a quality control program organized by the Association Franqaise de Cytometrie. All received diskettes containing
We evaluated laser scanning cytometry (LSC) by comparing nuclear DNA ploidy determined by LSC and by flow cytometry (FCM) i n 77 samples of human colorectal cancer from 48 patients. Both methods revealed an aneuploid peak in 30 (62.5%) of the cases, although two samples that were aneuploid by LSC we
S-phase fraction (SPF), estimated in the flow cytometric DNA histogram, is a prognostic factor in breast cancer. There are, however, some inherent difficulties in the estimation of SPF, such as the influence of debris, aggregates, and normal cells. Most of the available SPF calculation principles tr
Background: Analysis of the DNA cell cycle and glutathione content cannot be performed on viable cells, because the fluorescence emissions of the DNA-specific probe Hoechst 33342 and the glutathione-specific probe monobromobimane overlap completely. We decided to explore whether the emissions could